隶属于 FERRING SAS
相关临床试验
249
2 进行中
药物批准
149
批准总数
监管机构
5
监管机构数
成立时间
N/A
进行中（未招募）
2
0.8%
已完成
210
84.3%
招募中
2
0.8%
终止
26
10.4%
撤回
9
3.6%
- CorMedix Therapeutics CEO Joseph Todisco has signed an extended employment contract and will assume the role of Chairman of the Board, succeeding Myron Kaplan who transitions to Lead Independent Director. - The company appointed Mike Seckler as Executive Vice President and Chief Commercial Officer, bringing extensive experience from hematology, oncology, and gene therapy sectors. - Under Todisco's leadership, CorMedix has transformed from a single-product development company into a diversified commercial operation with positive cash flow and multiple therapeutic products. - The leadership changes position CorMedix to expand its commercial operations across multiple therapeutic areas and prepare for upcoming product launches.
- Sarasota Memorial Hospital's research institute is participating in two international clinical trials (ABLE-22 and ABLE-32) investigating gene therapy alternatives to bladder removal surgery for non-muscle-invasive bladder cancer patients. - The experimental treatment uses a non-replicating virus to deliver genes into bladder cancer cells, instructing them to produce proteins that boost immune response and directly attack cancer cells. - The trials target patients with intermediate-risk and high-risk NMIBC, conditions that affect 70-80% of all bladder cancer cases and often lead to quality-of-life-impacting surgeries due to high recurrence rates. - ABLE-32 will enroll up to 250 patients with intermediate-risk disease, while ABLE-22 will enroll up to 454 patients with high-risk disease who have not responded to BCG immunotherapy.
- Genetic Analysis launched the GA-map MHI GutHealth Reagent kit as a Research Use Only test, combining their GA-map platform with Ferring Pharmaceuticals' Microbiome Health Index biomarker for rapid microbiome diagnostics. - The test reduces processing time from weeks to hours and targets recurrent Clostridioides difficile infection patients, a condition affecting 500,000 individuals annually in the United States with 30,000 associated deaths. - The diagnostic tool enables clinicians to assess antibiotic-induced microbiome imbalances and monitor treatment response during microbiome restoration therapy with drugs like Ferring's FDA-approved Rebyota. - The kit is now available globally for Luminex xMAP users and launched in the USA through Pangea Laboratory, representing a new revenue stream for Genetic Analysis with expected gross margins of 80-85%.
- A phase 3b clinical trial demonstrated that Rebyota (fecal microbiota, live-jslm) administered via colonoscopy achieved a 95.1% treatment success rate in preventing recurrent C. difficile infection. - Only 9.8% of participants experienced Rebyota-related adverse events, all of which were mild and gastrointestinal in nature, confirming the safety profile of this administration method. - Patients reported significant quality of life improvements after treatment, with 89.7% experiencing symptom relief within the first month and substantial reductions in diarrhea, abdominal pain, and fatigue.
- The IRIS study represents the world's first randomized controlled trial specifically evaluating ovarian stimulation protocols in Indian infertile patients, addressing a historically under-researched population. - Individualized follitropin delta dosing achieved numerically higher ongoing pregnancy rates (22.2% vs 14.9%) and live birth rates (21.2% vs 14.9%) compared to conventional follitropin alfa dosing. - The study enrolled over 200 Indian women aged 21-40 years and demonstrated comparable safety profiles between treatment groups with no new safety concerns identified. - These findings support the use of personalized medicine approaches in assisted reproductive technology, potentially optimizing treatment outcomes for Indian patients undergoing IVF or ICSI procedures.
- The FDA has approved Ferring Pharmaceuticals' new drug product manufacturing hub in Parsippany, NJ, for production of ADSTILADRIN, the first FDA-approved intravesical gene therapy for high-risk BCG-unresponsive bladder cancer. - The approval expands Ferring's manufacturing capabilities to three sites dedicated to ADSTILADRIN production, triggering a final $200 million payment from Royalty Pharma as part of a financing agreement announced in 2023. - The 12,000 square foot state-of-the-art facility features renewable energy solutions and specialized technology to ensure stable supply for growing global demand, reinforcing Ferring's commitment to uro-oncology treatment innovation.
- Nadofaragene firadenovec demonstrated a 75% complete response rate at 3 months in Japanese patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, according to new Phase 3 trial data. - The gene therapy showed a favorable safety profile with 84.2% of treatment-related adverse events being Grade 1 and 15.8% Grade 2, with no Grade 3 or higher events reported in the Japanese patient population. - These results appear higher than previously reported in US trials and align with recent Mayo Clinic real-world data showing a 79% complete response rate, potentially establishing nadofaragene as a new standard of care for patients who would otherwise face bladder removal.
- The endometriosis clinical trial landscape is robust, featuring over 15 companies developing more than 20 potential therapies. - Recent clinical trial activity includes positive Phase II results for Hope Medicine's HMI-115 and TiumBio's Merigolix, alongside Lisata Therapeutics' preclinical research. - Key companies like Kissei Pharmaceutical, Mithra Pharmaceuticals, and Organon are advancing novel treatments, including Linzagolix and Estelle, to address unmet needs. - These emerging therapies aim to improve pain management and overall outcomes for the estimated 190 million women affected by endometriosis worldwide.
• Real-world data presented at ID Week 2024 confirms the continued efficacy and safety of Rebyota, a live biotherapeutic product, for recurrent Clostridioides difficile infection (rCDI) two years post-approval. • Research indicates reduced vancomycin susceptibility in Clostridioides difficile isolates correlates with diminished sustained clinical response, emphasizing the need for alternative treatment strategies. • Vedanta Biosciences has commenced a Phase 3 clinical trial (RESTORATiVE303) evaluating VE303, a live biotherapeutic product, for preventing recurrent Clostridioides difficile infection (rCDI). • A study showed that oral vancomycin prophylaxis significantly reduces Clostridioides difficile infection incidence during hospitalization for autologous stem cell transplant recipients.
- Real-world data presented at the 2025 ASCO Genitourinary Cancers Symposium indicates nadofaragene firadenovec demonstrates positive efficacy and safety outcomes in treating NMIBC. - The ABLE-32 phase 3B trial is underway to assess nadofaragene firadenovec in intermediate-risk NMIBC patients, addressing the unmet need for FDA-approved treatments. - Additional trials, including ABLE-22 and LUNAR, are exploring nadofaragene firadenovec as a monotherapy, in combination with other treatments, and in low-grade upper tract urothelial carcinoma. - Nadofaragene firadenovec, the first FDA-approved intravesical gene therapy, offers a novel approach by turning bladder wall cells into interferon microfactories to fight cancer.
